These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35110681)

  • 1. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.
    Biondini M; Kiepas A; El-Houjeiri L; Annis MG; Hsu BE; Fortier AM; Morin G; Martina JA; Sirois I; Aguilar-Mahecha A; Gruosso T; McGuirk S; Rose AAN; Tokat UM; Johnson RM; Sahin O; Bareke E; St-Pierre J; Park M; Basik M; Majewski J; Puertollano R; Pause A; Huang S; Keler T; Siegel PM
    Oncogene; 2022 Mar; 41(12):1701-1717. PubMed ID: 35110681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.
    Yardley DA; Weaver R; Melisko ME; Saleh MN; Arena FP; Forero A; Cigler T; Stopeck A; Citrin D; Oliff I; Bechhold R; Loutfi R; Garcia AA; Cruickshank S; Crowley E; Green J; Hawthorne T; Yellin MJ; Davis TA; Vahdat LT
    J Clin Oncol; 2015 May; 33(14):1609-19. PubMed ID: 25847941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.
    Bendell J; Saleh M; Rose AA; Siegel PM; Hart L; Sirpal S; Jones S; Green J; Crowley E; Simantov R; Keler T; Davis T; Vahdat L
    J Clin Oncol; 2014 Nov; 32(32):3619-25. PubMed ID: 25267761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.
    Roth M; Barris DM; Piperdi S; Kuo V; Everts S; Geller D; Houghton P; Kolb EA; Hawthorne T; Gill J; Gorlick R
    Pediatr Blood Cancer; 2016 Jan; 63(1):32-8. PubMed ID: 26305408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Billups CA; Hawthorne T; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2014 Oct; 61(10):1816-21. PubMed ID: 24912408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
    Ott PA; Pavlick AC; Johnson DB; Hart LL; Infante JR; Luke JJ; Lutzky J; Rothschild NE; Spitler LE; Cowey CL; Alizadeh AR; Salama AK; He Y; Hawthorne TR; Bagley RG; Zhang J; Turner CD; Hamid O
    Cancer; 2019 Apr; 125(7):1113-1123. PubMed ID: 30690710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.
    Rose AAN; Biondini M; Curiel R; Siegel PM
    Pharmacol Ther; 2017 Nov; 179():127-141. PubMed ID: 28546082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
    Rose AA; Grosset AA; Dong Z; Russo C; Macdonald PA; Bertos NR; St-Pierre Y; Simantov R; Hallett M; Park M; Gaboury L; Siegel PM
    Clin Cancer Res; 2010 Apr; 16(7):2147-56. PubMed ID: 20215530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
    Naumovski L; Junutula JR
    Curr Opin Mol Ther; 2010 Apr; 12(2):248-57. PubMed ID: 20373269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer.
    Li Z; Belitzky E; Blaha O; Cavaliere A; Katz SR; Aboian M; Melegari L; Rajabimoghadam K; Kurpiewski S; Zhu X; Marquez-Nostra B
    Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.
    Marquez-Nostra BV; Lee S; Laforest R; Vitale L; Nie X; Hyrc K; Keler T; Hawthorne T; Hoog J; Li S; Dehdashti F; Ma CX; Lapi SE
    Oncotarget; 2017 Nov; 8(61):104303-104314. PubMed ID: 29262642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE).
    Vaklavas C; Forero A
    BioDrugs; 2014 Jun; 28(3):253-63. PubMed ID: 24496926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer.
    Maric G; Rose AA; Annis MG; Siegel PM
    Onco Targets Ther; 2013; 6():839-52. PubMed ID: 23874106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.
    Ott PA; Hamid O; Pavlick AC; Kluger H; Kim KB; Boasberg PD; Simantov R; Crowley E; Green JA; Hawthorne T; Davis TA; Sznol M; Hwu P
    J Clin Oncol; 2014 Nov; 32(32):3659-66. PubMed ID: 25267741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
    Rose AA; Annis MG; Frederick DT; Biondini M; Dong Z; Kwong L; Chin L; Keler T; Hawthorne T; Watson IR; Flaherty KT; Siegel PM
    Clin Cancer Res; 2016 Dec; 22(24):6088-6098. PubMed ID: 27515299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer.
    Keir CH; Vahdat LT
    Expert Opin Biol Ther; 2012 Feb; 12(2):259-63. PubMed ID: 22229970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression pattern and prognostic impact of glycoprotein non-metastatic B (GPNMB) in triple-negative breast cancer.
    Huang YH; Chu PY; Chen JL; Huang CT; Huang CC; Tsai YF; Wang YL; Lien PJ; Tseng LM; Liu CY
    Sci Rep; 2021 Jun; 11(1):12171. PubMed ID: 34108545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.
    Vahdat LT; Schmid P; Forero-Torres A; Blackwell K; Telli ML; Melisko M; Möbus V; Cortes J; Montero AJ; Ma C; Nanda R; Wright GS; He Y; Hawthorne T; Bagley RG; Halim AB; Turner CD; Yardley DA
    NPJ Breast Cancer; 2021 May; 7(1):57. PubMed ID: 34016993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCN3/NOV promotes metastasis and tumor progression via GPNMB-induced EGFR activation in triple-negative breast cancer.
    Son S; Kim H; Lim H; Lee JH; Lee KM; Shin I
    Cell Death Dis; 2023 Feb; 14(2):81. PubMed ID: 36737605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB.
    Okita Y; Kimura M; Xie R; Chen C; Shen LT; Kojima Y; Suzuki H; Muratani M; Saitoh M; Semba K; Heldin CH; Kato M
    Sci Signal; 2017 Apr; 10(474):. PubMed ID: 28400538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.